Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial

Abstract Background We report results from a phase II randomised placebo-controlled trial assessing zibotentan, a highly selective endothelin receptor antagonist (ERA), in chronic kidney disease (CKD) secondary to systemic sclerosis (SSc). Methods This trial included three sub-studies: ZEBRA 1—a ran...

Full description

Bibliographic Details

Published in:	Arthritis Research & Therapy
Main Authors:	Edward P. Stern, Lauren V. Host, Ivy Wanjiku, K. Jane Escott, Peter S. Gilmour, Rachel Ochiel, Robert Unwin, Aine Burns, Voon H. Ong, Helen Cadiou, Aidan G. O’Keeffe, Christopher P. Denton
Format:	Article
Language:	English
Published:	BMC 2022-06-01
Subjects:	Scleroderma Renal crisis Chronic kidney disease Endothelin Zibotentan
Online Access:	https://doi.org/10.1186/s13075-022-02818-6